Abstract:Biomarkers play a crucial role in advancing precision medicine by enabling more targeted and individualized approaches to diagnosis and treatment. Various biofluids, including serum, plasma, cerebrospinal fluid (CSF), saliva, tears, pancreatic cyst fluids, and urine, have been identified as rich sources of potential for the early detection of disease biomarkers in conditions such as cancer, cardiovascular diseases, and neurodegenerative disorders. The analysis of plasma and serum in proteomics research encounters challenges due to their high complexity and the wide dynamic range of protein abundance. These factors impede the sensitivity, coverage, and precision of protein detection when employing mass spectrometry, a widely utilized technology in discovery proteomics. Conventional approaches such as Neat Plasma workflow are inefficient in accurately quantifying low-abundant proteins, including those associated with tissue leakage, immune response molecules, interleukins, cytokines, and interferons. Moreover, the manual nature of the workflow poses a significant hurdle in conducting large cohort studies. In this study, our focus is on comparing workflows for plasma proteomic profiling to establish a methodology that is not only sensitive and reproducible but also applicable for large cohort studies in biomarker discovery. Our investigation revealed that the Proteograph XT workflow outperforms other workflows in terms of plasma proteome depth, quantitative accuracy, and reproducibility while offering complete automation of sample preparation. Notably, Proteograph XT demonstrates versatility by applying it to various types of biofluids. Additionally, the proteins quantified widely cover secretory proteins in peripheral blood, and the pathway analysis enriched with relevant components such as interleukins, tissue necrosis factors, chemokines, and B and T cell receptors provides valuable insights. These proteins, often challenging to quantify in complex biological samples, hold potential as early detection markers for various diseases, thereby contributing to the improvement of patient care quality.

The revolution in high-throughput proteomics and AI

Frontiers in plasma proteome profiling platforms: innovations and applications

Plasma proteomic comparisons change as coverage expands for SomaLogic and Olink

Artificial Intelligence, Physiological Genomics, and Precision Medicine.

High-performance medicine: the convergence of human and artificial intelligence

Next generation plasma proteome profiling to monitor health and disease

Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification

Plasma proteomic associations with genetics and health in the UK Biobank

Deep plasma proteomics with data-independent acquisition: A fastlane towards biomarkers identification

Mapping biological influences on the human plasma proteome beyond the genome

Technical Assessment on Proteonano: A Robust Platform for Deep Plasma Proteomics Study

Promises and challenges of populational proteomics in health and disease

Deep Profiling of Plasma Proteoforms with Engineered Nanoparticles for Top-down Proteomics

A High-Confidence Human Plasma Proteome Reference Set with Estimated Concentrations in PeptideAtlas

Genomic atlas of the human plasma proteome

Advances and Challenges in Liquid Chromatography-Mass Spectrometry-based Proteomics Profiling for Clinical Applications

The convergence of traditional and digital biomarkers through AI-assisted biosensing: A new era in translational diagnostics?

Multiplatform Approach for Plasma Proteomics: Complementarity of Olink Proximity Extension Assay Technology to Mass Spectrometry-Based Protein Profiling.

A Multiplexed Quantitative Proteomics Approach to the Human Plasma Protein Signature

AI-driven Deep Visual Proteomics defines cell identity and heterogeneity

Advances in the Clinical Application of High-throughput Proteomics